Atnahs Pharma Denmark ApS: Financial statements 2020
CVR: 36699051
Source: annual report 2020, Danish Business Authority
01/04/2019 – 31/03/2020
Atnahs Pharma Denmark ApS (CVR 36699051) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,258,513 and a net result of DKK -1,418,130 compared with DKK -1,052,467 the year before. Equity in the 2020 report amounted to DKK -3,780,092.
- Gross Profit
- DKK -1,258,513
- Profit/Loss
- DKK -1,418,130
- Equity
- DKK -3,780,092
- Total Assets
- DKK 3,851,587
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -1.3 mio. | -1.4 mio. | -3.8 mio. | - |
| 2019 | - | 779 t. | -1.1 mio. | -2.4 mio. | - |
| 2018 | - | -1.4 mio. | -1.9 mio. | -1.3 mio. | - |
Official annual report
How creditworthy is Atnahs Pharma Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of February 24, 2020, Anthony Charles Playle has left the board of directors of Atnahs Pharma Denmark ApS.
About Atnahs Pharma Denmark ApS
Atnahs Pharma Denmark ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Pharmamentum ApS. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported revenue of EUR 52,583,756 and a net result of EUR 12,487 compared with DKK 47,843 the year before. Equity in the 2026 report amounted to EUR 2,094,136.